[Retracted] The Prognostic Value of Leucine‐Rich α2 Glycoprotein 1 in Pediatric Spinal Cord Injury

Abstract

Objective. Leucine-rich α2 glycoprotein 1 (LRG1) is a novel cytokine, which is believed to be involved in the inflammatory process of a series of diseases. However, the relationship between LRG1 and spinal cord injury (SCI) has not been reported. The purpose of our study is to determine the predictive value of LRG1 for the prognosis of pediatric SCI (PSCI). Methods. This study recruited 64 patients with confirmed PSCI and 40 healthy controls at Foshan Traditional Chinese Medicine Hospital from January 2016 to December 2020. The clinical information of all participants at the time of admission was recorded. Peripheral blood was collected, and commercial reagents were used to detect the level of serum LRG1. At the same time, the International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI) was used to assess the severity of PSCI. Results. All participants were divided into PSCI group ( n = 64 ) and NC group ( n = 40 ). There was no significant difference in clinical information (age, gender, heart rate, systolic blood pressure, diastolic blood pressure, sampling time from injury, white blood cells, and C-reactive protein) between the two groups ( p > 0.05 ). According to the interquartile range of serum LRG1, we compared the motor and sensory scores of ISNCSCI and found that serum LRG1 levels were negatively correlated with the prognosis of PSCI patients ( p < 0.001 ). The results of receiver operating curve (ROC) showed that the sensitivity, specificity, and AUC (Area Under the Curve) of serum LRG1 level in predicting the prognosis of PSCI were 68.4%, 69.1%, and 0.705, respectively. The cut-off value of serum LRG1 level predicting the prognosis of PSCI is 21.1 μg/ml. Conclusions. Serum LRG1 level is significantly increased in PSCI patients, and the elevated LRG1 level is negatively correlated with the prognosis of PSCI patients. Serum LRG1 may be a potentially useful biomarker for predicting PSCI.

Applying multi-omics data to study the genetic background of bovine respiratory disease infection in feedlot crossbred cattle

“…Blood transcriptomic and metabolomic biomarkers have been proposed to be used in the identification of BRD cattle in feedlots ( Blakebrough-Hall et al, 2020 ; Sun et al, 2020 ). In this study, 101 DE genes were identified and the most informative marker LRG1 has been previously identified as a potential biomarker for different infections (e.g., active tuberculosis) in humans ( Wu et al, 2015 ; Fujimoto et al, 2020 ; Yang et al, 2020 ; Ma et al, 2021 ). We also found 31 metabolites were significantly associated with BRD infection, 13 of which were consistent with significant metabolites (e.g., citric acid, d -mannose, and acetic acid) identified by Blakebrough-Hall et al (2020) , even though the metabolite profiles used in the two studies were not exactly the same.…”

Research Progress on Leucine-Rich Alpha-2 Glycoprotein 1: A Review

“…There were relatively comprehensive clinical and basic studies on the function of LRG1 in stroke diseases. Serum level of LRG1 was identified as a potential indicator for the prediction of cardioembolic stroke, as well as pediatric spinal cord injury Ma et al, 2021). Apolipoprotein CII, LRG1, and C-reactive protein expression were significantly downregulated in poststroke depression relative to stroke subjects (Zhan et al, 2014).…”

Nogo-A Is a Potential Prognostic Marker for Spinal Cord Injury

“…According to statistics, the annual cost of SCI in the United States is estimated to be between 5 million and 9 million US dollars, while in Australia, the figure is about 2 billion US dollars [ 5 – 7 ]. The pathogenic mechanism after SCI has not yet been fully elucidated, and the prognosis is poor, which affects the self-care ability of patients [ 8 ]. Therefore, finding prognostic markers for SCI and precise treatment are the top priorities.…”